| Literature DB >> 15036940 |
Tetsuzo Tauchi1, Kazuma Ohyashiki.
Abstract
Despite high rates of hematologic and cytogenetic responses to imatinib therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of Ph-positive leukemia. The high frequency of BCR-ABL mutations and amplifications represents the high degree of heterogeneity in patients with advanced phase of CML, in whom multiple leukemic clones may exist. Therefore, a single inhibitor is unlikely to able to block all mutants.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15036940 DOI： 10.1016/j.leukres.2003.10.007
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156